[Role of dopaminergic agonists].
Identifieur interne : 000127 ( Ncbi/Curation ); précédent : 000126; suivant : 000128[Role of dopaminergic agonists].
Auteurs : O. Rascol [France] ; J L MontastrucSource :
- Revue neurologique [ 0035-3787 ] ; 2000.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists.
- drug therapy : Parkinson Disease.
- Humans.
Abstract
The usefulness of an initial treatment of Parkinson's disease with a dopamine agonist has now been studied for more than 20 years. The first clinical trials compared the long-term out come of patients receiving early bromocriptine or lisuride to those receiving initial L-dopa. These pilot data suggested that the early use of these agonists (combined early or supplemented later with low doses of L-dopa) reduced the risk of occurence of motor complications such as dyskinesia and/or fluctuations. These initial conclusions were however criticised because of methodological limitations in study design. The recent results from new large prospective randomized double-blind 5-year L-dopa-controlled trials using newer dopamine agonists (cabergoline and ropinirole) confirmed the findings of the previous pilot studies. Therefore, one now generally agrees that the early use of such agonists (to which low doses of L-dopa may be added as a second step if necessary to maintain an adequate control of parkinsonian symptoms) is useful to reduce the risk of occurence of motor complications. This result is achieved without a major increase in the risk of other dopaminergic adverse events (digestive, cardiovascular, psychiatric), specially in 'young' patients (before 70 years).
PubMed: 10916043
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001357
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001316
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001316
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000127
Links to Exploration step
pubmed:10916043Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Role of dopaminergic agonists].</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Service de Pharmacologie Clinique, Centre d'Investigation Clinique, INSERM U455, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre d'Investigation Clinique, INSERM U455, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:10916043</idno><idno type="pmid">10916043</idno><idno type="wicri:Area/PubMed/Corpus">001357</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001357</idno><idno type="wicri:Area/PubMed/Curation">001316</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001316</idno><idno type="wicri:Area/PubMed/Checkpoint">001316</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001316</idno><idno type="wicri:Area/Ncbi/Merge">000127</idno><idno type="wicri:Area/Ncbi/Curation">000127</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Role of dopaminergic agonists].</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Service de Pharmacologie Clinique, Centre d'Investigation Clinique, INSERM U455, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Clinique, Centre d'Investigation Clinique, INSERM U455, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term><term>Dopamine Agonists (therapeutic use)</term><term>Humans</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The usefulness of an initial treatment of Parkinson's disease with a dopamine agonist has now been studied for more than 20 years. The first clinical trials compared the long-term out come of patients receiving early bromocriptine or lisuride to those receiving initial L-dopa. These pilot data suggested that the early use of these agonists (combined early or supplemented later with low doses of L-dopa) reduced the risk of occurence of motor complications such as dyskinesia and/or fluctuations. These initial conclusions were however criticised because of methodological limitations in study design. The recent results from new large prospective randomized double-blind 5-year L-dopa-controlled trials using newer dopamine agonists (cabergoline and ropinirole) confirmed the findings of the previous pilot studies. Therefore, one now generally agrees that the early use of such agonists (to which low doses of L-dopa may be added as a second step if necessary to maintain an adequate control of parkinsonian symptoms) is useful to reduce the risk of occurence of motor complications. This result is achieved without a major increase in the risk of other dopaminergic adverse events (digestive, cardiovascular, psychiatric), specially in 'young' patients (before 70 years).</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000127 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000127 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:10916043
|texte= [Role of dopaminergic agonists].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:10916043" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |